A New Chapter in FreeStyle Libre Technology

Abbott’s latest CGM sensor offers new benefit to U.S. insulin pump users, reinforcing company’s position as a leader in diabetes care.

Strategy and Strength|Jan.23, 2024

A new year brings exciting new developments in diabetes management.

For the first time, people in the United States who use Abbott’s world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology to manage their diabetes can experience the therapeutic benefits of an automated insulin delivery (AID) system that helps predict and prevent high and low blood sugar.

That’s because Abbott’s new FreeStyle Libre 2 Plus sensor integrates with the t:slim X2 insulin pump from Tandem Diabetes Care Inc.

The FreeStyle Libre 2 Plus sensor, which is the modified FreeStyle Libre 2 sensor cleared in 2023 by the Food & Drug Administration for use with AID systems, is the first and only CGM available in the United States with a wear time of 15 days1 for both adults and children, thereby offering greater convenience and cost savings to people with diabetes.

This is the latest in a series of partnerships aimed at improving and streamlining diabetes care. Last year Abbott integrated its FreeStyle Libre 3 sensor with CamDiab’s CamAPS FX mobile app and Ypsomed’s mylife YpsoPump to implement an AID system in Europe. 

The broader reach resulting from these partnerships will strengthen Abbott’s position in the CGM market and expand opportunities for growth.

The FreeStyle Libre 2 Plus sensor connects wirelessly to the pump and automatically sends it glucose readings every minute2. Users can see their glucose data on the pump and in the t:connect app3. The t:slim X2 pump with Control-IQ technology predicts glucose levels 30 minutes into the future, automatically adjusting insulin delivery every five minutes based on CGM readings and delivering automatic correction boluses (up to one per hour) to help prevent hyperglycemia4.

Abbott is working with several insulin pump and smart insulin pen manufacturers to integrate their systems with FreeStyle Libre technology as soon as possible.

Click here for more information on how Abbott’s FreeStyle Libre technology plays an essential role in powering AID systems that take the guesswork out of managing diabetes.


1Based on patient applied sensors currently on the market in the U.S.
2 FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump. Glucose data is visualized on the t:connect mobile app and t:slim X2 insulin pump.
3 The information on the t:connect mobile app display may not be identical to the current status of your pump. Wireless uploads from the t:connect mobile app to the cloud-based t:connect web application require a compatible phone and an internet or wireless data connection. Uploads to the t:connect web application do not take place in real time and should not be relied upon by healthcare providers or caregivers for remote patient monitoring. Standard carrier data rates may apply.
4If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value.


t:slim X2 Insulin Pump


Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

t:slim X2 Insulin Pump

RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater.

WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.


Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.